BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CFO Brian C. Stephenson sold 8,500 shares of BridgeBio Pharma stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $33.19, for a total value of $282,115.00. Following the completion of the transaction, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,400,780.16. This represents a 7.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.
BridgeBio Pharma Trading Down 5.4 %
BridgeBio Pharma stock traded down $1.89 during trading hours on Monday, hitting $33.01. 3,282,866 shares of the stock traded hands, compared to its average volume of 3,176,007. The firm's 50-day moving average price is $32.79 and its two-hundred day moving average price is $28.40. The company has a market cap of $6.28 billion, a PE ratio of -11.58 and a beta of 1.07. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to analysts' expectations of $4.04 million. On average, sell-side analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.
Institutional Trading of BridgeBio Pharma
A number of hedge funds have recently made changes to their positions in BBIO. Farallon Capital Management LLC boosted its position in shares of BridgeBio Pharma by 140.1% in the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company's stock worth $115,111,000 after purchasing an additional 2,448,000 shares in the last quarter. Woodline Partners LP boosted its position in shares of BridgeBio Pharma by 132.9% in the 4th quarter. Woodline Partners LP now owns 2,211,521 shares of the company's stock worth $60,684,000 after purchasing an additional 1,261,772 shares in the last quarter. Norges Bank bought a new stake in shares of BridgeBio Pharma in the 4th quarter worth approximately $29,237,000. Alyeska Investment Group L.P. bought a new stake in shares of BridgeBio Pharma in the 4th quarter worth approximately $25,805,000. Finally, Capital Research Global Investors boosted its position in shares of BridgeBio Pharma by 34.9% in the 4th quarter. Capital Research Global Investors now owns 3,526,747 shares of the company's stock worth $96,774,000 after purchasing an additional 912,439 shares in the last quarter. 99.85% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several research firms have recently commented on BBIO. Cantor Fitzgerald reiterated an "overweight" rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a report on Friday, February 21st. Citigroup boosted their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a report on Friday, February 21st. HC Wainwright restated a "buy" rating and set a $49.00 price target on shares of BridgeBio Pharma in a report on Thursday, February 13th. Bank of America boosted their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, November 25th. Finally, Evercore ISI boosted their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat.com, BridgeBio Pharma has a consensus rating of "Moderate Buy" and an average price target of $51.67.
Read Our Latest Analysis on BridgeBio Pharma
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
See Also
Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
